FDA Pumps Brakes on Big Pharma’s Latest Alzheimer’s Cash Grab
For families grappling with the heartbreak of Alzheimer’s, any glimmer of hope can feel like a lifeline.
So when drugmakers tout shiny new treatments that promise to halt the disease’s merciless march, it’s tempting to believe the hype.
Especially with over 55 million desperate folks worldwide staring down this devastating diagnosis.
But look closer and you’ll see profits trump patient welfare every single time—a truth laid bare by the FDA’s recent smackdown of a pharma giant’s latest so-called silver bullet.
Before you buy what they’re peddling, get the real story on how Big Pharma preys on our most vulnerable for financial gain!
Just as pharma giant Eli Lilly was ready to pop champagne over fast-track approval for its Alzheimer’s drug donanemab, the FDA abruptly halted the party.
Regulators will instead convene an external panel to scrutinize the treatment’s safety and effectiveness, pushing any green light to year’s end or beyond.
The drug, one of a trio of “anti-amyloid antibodies”, aims to clear brain plaques associated with Alzheimer’s. Early trials showed it slowed cognitive decline by 35% in certain patients—but also triggered dangerous brain swelling and bleeding in others.
Lilly’s hardly alone in trying to cash in on the Alzheimer’s crisis. Biogen’s similar drug Aduhelm won approval in 2021 despite threadbare evidence of benefits and a laundry list of risks. Same goes for Eisai’s Leqembi earlier this year.
Notice a pattern? These pharma giants see dollar signs, not people, when they look at the mushrooming dementia epidemic. And they’re banking on our collective despair to blind us to red flags.
Big Pharma will gladly charge $26,000 a year for medications that, at best, briefly brake decline in cherry-picked patients—never mind the potential for deadly brain bleeds. All while raking in projected BILLIONS.
Greed masquerading as compassion? You bet. While Big Pharma plays the hero, real people pay the price.
Thankfully, we’re not helpless as these drug pushers vie for our pocketbooks. Ironclad research proves that simple, free lifestyle shifts can work wonders for warding off dementia:
Eat like a Mediterranean.
Colorful fruits and veggies, fatty fish, beans, nuts and olive oil nourish brain cells.
Break a sweat.
Aim for 30 minutes of heart-pumping activity most days to keep your thinker nimble.
Flex your mental muscles.
Crosswords, arts and crafts, music – anything that challenges your noodle builds cognitive reserves.
Stick to a sleep schedule.
Ample, high-quality rest is like a power cleanse for your neural networks.
Stay social.
Fight isolation and loneliness, which can fast-track mental decline.
Studies also suggest that phosphatidylserine (PS) supplements and gingko biloba may help prevent the age-related cognitive decline associated with Alzheimer’s. Consider safe supplementation and always consult your doctor or integrative health professional.
Last but not least, be sure to review the side effects of any medications you may be on with your doctor. The fewer the meds, the better.
While these habits aren’t an iron-clad guarantee, they’ll shore up your brain’s defenses far better than any pricey pill.
In Your Corner,
Dr. Allan Spreen
P.S. Click here to learn about Big Pharma’s risky treatment for this deadly sleep condition.
In Case You Missed It
- Cracking the Crohn’s code: how gut bacteria can hijack your health.
- Learn about the surprising four-legged stress-buster.
- The dirt-cheap diabetes defender Big Pharma hopes you’ll NEVER discover.
- Six expert-backed remedies for menopause relief.
- The spicy secret to taming type 2 diabetes.
Sources:
